Literature DB >> 9793163

Myocardial dysfunction in sepsis: clinical and experimental investigations.

A F Suffredini1.   

Abstract

OBJECTIVE: To review the clinical manifestations and mechanisms of cardiac dysfunction in septic shock.
METHODS: Literature review of selected clinical studies and animal models.
RESULTS: Depressed myocardial contractile function is a common consequence of severe infections. Bacterial factors, in conjunction with host inflammatory mediators, produce a profile of reversible cardiac dysfunction manifested by a decrease in ventricular ejection fraction, ventricular dilatation, and increased cardiac output. Global ischemia is not the major mechanism that mediates cardiac dysfunction during sepsis. Inflammatory mediators contribute to myocardial dysfunction by damaging the coronary microcirculation and contributing to myocardial edema and cardiocyte damage. However, trials of anti-inflammatory agents have not prevented or increased the rate of reversal of septic shock or improved survival. The link between nitric oxide and clinical myocardial depression remains unclear, as nonselective nitric oxide synthase inhibition does not block the development of ventricular dysfunction.
CONCLUSIONS: Serious bacterial infections result in inflammatory injury to the heart manifested by a common profile of cardiac dysfunction. Therapy remains limited to treatment of the infection with antibiotics and supportive care, with fluid resuscitation and selective use of inotropes and vasopressors. Experimental models suggest that new anti-inflammatory strategies (e.g. tyrosine kinase inhibitors) may offer some advantages over those that target a single mediator; these agents remain to be clinically evaluated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9793163

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  1 in total

1.  Change in stroke volume in response to fluid challenge: assessment using esophageal Doppler.

Authors:  Margareta Roeck; Stephan M Jakob; Thomas Boehlen; Lukas Brander; Rafael Knuesel; Jukka Takala
Journal:  Intensive Care Med       Date:  2003-04-09       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.